BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
| Revenue (Most Recent Fiscal Year) | $3.81B |
| Net Income (Most Recent Fiscal Year) | $-644.79M |
| PE Ratio (Current Year Earnings Estimate) | 325.65 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.86 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6.43% |
| Net Margin (Trailing 12 Months) | -9.40% |
| Return on Equity (Trailing 12 Months) | -7.55% |
| Return on Assets (Trailing 12 Months) | -4.42% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.96 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | 1.36 |
| Book Value per Share (Most Recent Fiscal Quarter) | $35.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.22 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.72 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 99.25M |
| Free Float | 92.68M |
| Market Capitalization | $24.48B |
| Average Volume (Last 20 Days) | 0.35M |
| Beta (Past 60 Months) | 0.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.62% |
| Percentage Held By Institutions (Latest 13F Reports) | 48.55% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |